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1  | INTRODUC TION
Coronaviruses, such as severe acute respiratory syndrome coronavi-
rus (SARS-CoV) and Middle East respiratory syndrome coronavirus 
(MERS-CoV), are pathogens that largely affect and subsequently 
cause symptoms of the respiratory system. An outbreak in the city 
of Wuhan in December of 2019 saw the introduction of a new coro-
navirus strain, severe acute respiratory syndrome coronavirus 2 
(SARS-CoV-2), named coronavirus disease 2019 (COVID-19) by the 
World Health Organization (WHO) in February 2020. This novel 
virus, which has consequently sparked a global pandemic, has also 
been widely reported to display a range of respiratory manifesta-
tions. Milder, and most commonly, symptoms include fever, fatigue 
and cough; however, more severe cases of the disease can induce 
respiratory distress, renal and cardiac failure and eventually death.1
In addition to respiratory symptoms, reports are emerging of neu-
rological manifestations of SARS-CoV-2, which range from milder pre-
sentations such as headache to severe complications such as seizures 
and strokes. We provide a comprehensive review of the neurological 
manifestations of SARS-CoV-2 and its outcomes on mortality and 
propose the implications this has on clinical practice now and in the 
future.
1.1 | Literature search strategy
A comprehensive electronic literature search was done on PubMed, 
SCOPUS, Embase, Cochrane database, Google Scholar and Ovid in 
accordance with Preferred Reporting Items for Systematic Reviews 
and Meta-analysis (PRISMA) guidelines to identify the articles that 
discussed the neurological presentations and relation with COVID-
19. Keywords used were “Neurology” “COVID-19” “SARS-CoV2” 
“Neurological manifestations” “Nervous system” “Guillain-Barre 
syndrome” “Neuropathy” “Outcomes” “Stroke” “Nerve” “Critical 
care”. The search terms were used as keywords and in combination 
as MeSH terms to maximize the output from literature findings. A 
staged literature search was done, whereby a separate literature 
search was performed for each section within this article and all 
the relevant studies were identified and summarized separately. If 
a paper is reporting on many aspects of COVID-19 and neurology 
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The novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2), was first identified in December of 2019 in the city of Wuhan, China. Since 
the outbreak, various reports detail its symptoms and outcomes, primarily focusing 
on respiratory complications. However, reports are emerging of the virus’ effects 
systemically, including that of the nervous system. A review of all current published 
literature was conducted, and we report that headache and anosmia were common 
neurological manifestations of SARS-CoV-2. Less common symptoms include seizure, 
stroke and isolated cases of Guillain-Barre syndrome. Further research is now war-
ranted to precisely determine the relationship between those patients developing 
neurological sequelae, their clinical state and any subsequent morbidity and mortality.
K E Y W O R D S
COVID-19, nervous system, neurology, SARS-CoV-2
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction 
in any medium, provided the original work is properly cited and is not used for commercial purposes.
© 2020 The Authors. Acta Neurologica Scandinavica published by John Wiley & Sons Ltd
2  |     WHITTAKER ET Al.
aspect, then the results have been shared between different parts 
of this review. The relevant articles are cited and referenced within 
each section separately. No limit placed on publication time or lan-
guage of the article. All the relevant articles were identified and 
screened by three authors; the results are summarized in narrative 
manner in each relevant section within the text of this review. A 
summary table of each section is provided where appropriate.
Studies were included if they have reported outcomes on any 
aspects of neurology in relation to COVID-19; the main exclusion cri-
teria were editorials, commentary, narrative reviews with no reports 
on case outcomes or proposed treatment method. All the studies 
and data collection were done by two authors (AW and MA), and 
disagreements were resolved by consensus and involvement of se-
nior author (AH).
2  | RESULTS
PRISMA flow chart is reported as in Figure 1. A total of 339 articles 
were found; after removal of duplicates and non-original research 
papers, a total of 38 articles were used for full-text screening; and 
finally, only 31 studies met the final inclusion criteria and were in-
cluded in our study. They are summarized in Table 1. Among those 
studies, there were 13 case reports, 2 observation studies of be-
tween 8-382 case-cohort size, 13 retrospective, 2 prospective 
and 1 cross-sectional study. Among the 31 studies, 7 reported on 
Guillain-Barre syndrome, 11 reported on headache, 5 reported on 
olfactory dysfunction, and 5 reported on acute cerebrovascular 
accidents.
2.1 | Mechanism of neurological pathology
The respiratory manifestations of SARS-CoV-2 are well documented 
and known. There is an increasing body of significant anecdotal evi-
dence suggesting anosmia as being a symptom of SARS-CoV-2, giv-
ing rise to the possibility that there may be a degree of neurological 
involvement with the infection.
It has been proposed that SARS-CoV-2 gains entry to the CNS by 
one of two ways: firstly, by systemic vascular dissemination and, sec-
ondly, more locally across the cribriform plate of the ethmoid bone, 
which may or may not have implications regarding the much-re-
ported anosmia that patients with SARS-CoV-2 experience.2 Baig 
et al propose that once in the systemic circulation, the virus invades 
neural tissue due to its properties of neurotropism. Here, it binds to 
and interacts with angiotensin-converting enzyme 2 (ACE2) recep-
tors in the capillary endothelium.2
There is certainly prescience for SARS-CoV-2 possessing such 
neuroinvasive properties. Like its sister virus SARS-CoV responsi-
ble for the outbreak in 2003, SARS-CoV-2 gains entry to cells via 
ACE2, which it binds via spike proteins.2 ACE2 has previously been 
reported to be expressed in the epithelium of the upper and lower 
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airways, alongside the capillary endothelium of the central nervous 
system (CNS).3 A study conducted into the structural integrity of 
the SARS-CoV-2 spike glycoprotein, revealed an 10- to 20-fold in-
crease in affinity to ACE2 when compared to the SARS-CoV spike 
protein.4 This could be explained by the fact that whilst structurally 
similar, the two spike glycoproteins are not identical, as identified 
by a BLASTp search of the two structures.4 This may also explain 
why differences in the prevalence of neurological manifestations are 
being reported between the sister viruses.
Yet, it must be noted that not all human cell lines which express 
ACE2 are liable to infection with the novel coronavirus. However, de-
spite the paucity of data regarding the neurotropism of SARS-CoV-2, 
there is an increasing awareness that its neurological manifestations 
are something to be recognized alongside its more well-understood 
respiratory presentation.
2.2 | Neurological manifestations
After having conducted a review of all the literature on PubMed 
pertaining to the neurological manifestation of SARS-CoV-2 using 
key terms such as “Covid AND neurology”; “Covid AND nervous 
system”, we summarize the findings of 31 such papers that were 
available to review at the time in Table 1. Key symptoms reported 
were headache and dysfunction of olfaction and gustatory sensa-
tion. However, it is important to note that no papers as of yet have 
sought to determine whether neurological involvement is a predictor 
of poor outcomes in patients with SARS-CoV-2, something which we 
feel may be worthwhile.
It is worth mentioning that all studies in this area to date limit 
themselves to patients admitted to hospital with SARS-CoV-2. Such 
a population are more likely to have significant other co-morbidities, 
and this may influence the rate of neurological sequelae. Studies in-
vestigating the incidence of neurological and other extra-respiratory 
symptoms in patients within the community are called for. Whether 
neurological manifestations of SARS-CoV-2 are as a direct result of 
the neuroinvasive properties of the virus or as an indirect conse-
quence of downstream multi-organ dysfunction and aberrant bio-
chemistry is yet to be fully understood, most likely however, is it a 
combination of both.
2.2.1 | General neurological symptoms
Given the global nature of SARS-CoV-2, the lack of any large-scale 
observational studies investigating the CNS involvement of the 
novel coronavirus is surprising. Numerous individual case reports 
exist which suggests that some patients exhibit neuropsychiatric 
complications of the virus such as altered consciousness5 and en-
cephalopathy6; however, such reports are limited by their power. Of 
the limited published research available, most centre in China from 
the beginning of the SARS-CoV-2 pandemic. An early study from 
city of Wuhan, China, of 214 hospitalized patients with SARS-CoV-2 
reported that over a third (36.4%) of patients had some degree of 
neurological involvement suggesting that this may be an under-
reported and overlooked component of the disease course. They 
noted that headache and dizziness were the two most reported CNS 
manifestations at 17% and 13%, respectively. The incidence of more 
severe neurological sequelae such as cerebrovascular accidents and 
seizures was low at 3% and 0.5%, respectively. Those with “severe” 
infections with SARS-CoV-2 were found to be more likely to suf-
fer from neurological complications; however, the authors did not 
specify the methodology of distinguishing between a severe and 
non-severe infection with SARS-CoV-2.7
Interestingly, they noted that most neurological manifestations 
occurred early on in the disease which may pose to be an important 
early predictor of future clinical deterioration. Another similar such 
retrospective series by Chen et al from the city of Wuhan described 
that confusion (9%) and headache (8%) were symptoms reported by 
such patients; importantly however, neurological complaints were 
significantly less prevalent than the typical respiratory symptoms 
of cough (82%) and dyspnoea (31%).8 More significant and poten-
tially long-lasting neurological complications of SARS-CoV-2 were 
highlighted by Li et al in a study of 221 patients, and 6% developed 
severe neurological disease: ischaemic stroke, haemorrhage of ce-
rebral vein thrombosis, of which a significant proportion died as a 
result.9
2.2.2 | Stroke
Worryingly, Oxley et al10 reported five cases of large vessel stroke 
in patients younger than 50 who had a diagnosis of SARS-CoV-2. 
The youngest two patients, aged 33 and 37, had no previous medical 
history. Two further studies detailing the rate of thromboembolic 
complications in patients with SARS-CoV-2 noted the incidence of 
ischaemic stroke to be 1.6%11 and 2.5%,12 respectively. Both authors 
recognized that the incidence of thrombotic complications was re-
markably high for their particular institutions. There are clearly addi-
tional risk factors predisposing patients with SARS-CoV-2 to develop 
thromboembolic stroke beyond the traditional cardiovascular and 
metabolic co-morbidities and those pertinent to a protracted stay 
within intensive care settings.
The thrombo-inflammatory nature that SARS-Cov-2 predisposes 
patients to, was described by Connor and colleagues who reported 
the coagulative parameters in 16 critically ill patients.13 They found 
that fibrinogen (94%), platelet (62%) and D-dimer (100%) levels were 
increased, as well as interleukin-6 (IL-6) (100%). They propose a cor-
relation between inflammation and subsequent coagulopathy, by 
IL-6 and fibrinogen, respectively.13 Upon damage to the alveoli, an 
inflammatory state is generated, and as a result, the production of 
inflammatory cytokines is released, including IL-6.
The downstream effects are broadly categorized into two se-
quelae: firstly, the production of pro-coagulative factors and, sec-
ondly, damage to capillary endothelium resulting in dysregulation of 
its anti-thrombotic properties. Both of which result in the formation 
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of microvascular thrombosis, that in turn have the potential to em-
bolize systemically.13 The pathophysiology of pro-thrombotic states 
following viral infection has been extensively documented and mir-
rors the proposed mechanism by Connor et al However, we must 
also consider the possibility that the predisposition to coagulopathy 
and thrombotic events may well be explained by the long stays in 
ITU and consequent immobility.
2.2.3 | Guillain-barre syndrome
There have also been eleven confirmed case reports and another po-
tential report of Guillain-Barre syndrome (GBS) as being a significant 
neurological sequelae of SARS-CoV-2. Of the eleven cases in published 
literature, there is considerable variability in the onset of features of 
GBS and the typical respiratory symptoms of SARS-CoV-2. One paper 
reported symptoms of GBS at initial presentation to healthcare set-
tings alongside only mild fever,14 whereas a further nine patients re-
ported symptoms of GBS, five to eleven days post-diagnosis with the 
novel coronavirus15-19.Despite the inconsistent onset of symptoms in 
relation to the diagnosis of COVID-19, it is reassuring that the majority 
of reports describe consistent clinical features of marked lower limb 
weakness over upper limb and loss of deep tendon reflexes with varia-
ble sensory abnormalities. Interestingly however, raised cerebrospinal 
fluid protein was not universal in this cohort of patients, and in patients 
with significant respiratory compromise from SARS-CoV-2, measuring 
vital capacity due to neuromuscular failure from GBS to further sup-
port the diagnosis may not be plausible.
Another report by Zhao et al suggests GBS as a presenting 
symptom of the novel coronavirus but it is unclear whether this is 
a true association or merely coincidental.20 It is well documented 
that GBS is associated with recent inoculation from a potential range 
of pathogens, which in itself can explain the clinical heterogenic-
ity of the disease.21 Several mechanisms by which a virus induces 
an acute areflexic state in GBS have been proposed. Most likely is 
that antibodies against surface glycoproteins are produced against 
a pathogen which also respond to similar native protein structures 
found of the surface of neurones leading to the clinical features 
seen in GBS.19 Other plausible theories include one described by 
McGonagle et al who describe a “macrophage activation syndrome,” 
also known as cytokine storm, and the subsequent hyperinflamma-
tion may also be implicated in the pathogenesis of GBS in patients 
with SARS-CoV-2.22
A clear time lag between infection with the primary causative 
pathogen and development of neurological sequelae is the classic 
phenotype of GBS and has been described as the “post-infectious” 
presentation. However, it is clear that from some case reports, this 
post-infectious phenotype may not explain why a select number of 
patients present with either concurrent symptoms of SARS-CoV-2 
and neurological involvement or those that present with GBS ini-
tially. Zhao et al20 proposed a so-called “parainfectious” profile pat-
tern whereby GBS occurs at the same time of an acute episode of 
infection. This may go some way to explain some of the early onset 
cases of GBS, some of which preceded without significant respira-
tory involvement and in the absence of a history of any other plausi-
ble infection known to cause GBS.
Toscano et al15 raised an important point in being able to dis-
tinguish between GBS and critical illness polyneuropathy, particu-
larly in patients with SARS-CoV-2 who have prolonged admission to 
intensive care. These consequences of extended intensive care are 
typically seen later in the course of major illness than GBS but as we 
have explored, relying on purely time as a differentiator may prove 
to be difficult.
Historical research has shown that coronaviruses do have the 
potential to induce demyelinating disease in mice, albeit a central 
demyelination type picture.23 There has been an interesting case 
of GBS overlapping with Bickerstaff's encephalitis documented in 
the previous MERS-CoV24 outbreak and a report of a 5-year-old 
developing GBS after contraction of coronavirus OC43.25 So, in 
combination with animal models, previous reports of neurologi-
cal involvement in sister viruses and current emerging reports, it 
does seem that GBS is associated with the ongoing SARS-CoV-2 
pandemic. But due to so few published reports and the difficulty 
in proving a direct cause and effect relationship between a sin-
gle pathogen, it may be complex to explore this further in clinical 
practice. The neurological symptoms reported by patients are rep-
resented in Figure 2.
2.2.4 | Critical illness polyneuropathy/myopathy
The long-stay admissions that some patients are currently expe-
riencing may also pose another issue, that of post-intensive care 
syndrome (PICS), in particular critical illness polyneuropathy and 
myopathy (CIPNM). Case reports from SARS-CoV detail patients 
who experienced CIPNM following infection with the virus.26 The 
underlying mechanism, though not fully understood, is thought to 
be due to systemic inflammatory response syndrome (SIRS) that re-
sults.27 This mediates the release of pro-inflammatory cytokines and 
free radicals, which affect the microcirculation of both the central 
and peripheral nervous system by reducing oxygen and nutrient de-
livery.27 It is also important to note that risk factors for PICS have 
F I G U R E  2   Illustration of reported neurological manifestations 
of SARS-CoV-2
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been identified and include long durations of mechanical ventilation, 
hypoxia and sepsis, features that are common to severe SARS-CoV-2 
cases.27 Yet, no reports detail such symptoms in SARS-CoV-2 pa-
tients thus far; however, due to the similarity of the sister viruses, 
this may be a potential long-term complication.
2.3 | How neurology affects 
outcomes and mortality
Current published studies have suggested that neurological involve-
ment in the pathogenesis of SARS-CoV-2 does seem to be associated 
with a more “severe” infection and subsequent mortality. However 
currently, no direct cause and effect has been attributed to neuro-
logical deterioration in patients with SARS-CoV-2 and this relation-
ship could just as plausibly be explained by association with other 
multi-organ system failures. The direct effect on mortality and mor-
bidity in such “neurological involving” patients is yet to be elucidated.
Interestingly, peripheral nervous system involvement by way 
of anosmia has been shown to be the initial presentation of SARS-
CoV-2 in 36% of patients a recent Spanish case-control study. These 
so-called smell and taste disorders (STD) were found to be signifi-
cantly more prevalent in SARS-CoV-2 patients than in influenza 
patients.28 This opens the possibility of more prompt isolation of 
suspected cases and control of the pandemic if the typical symptoms 
of fever and cough are indeed preceded by anosmia, even if only for 
a select group of people.
It has been proposed that SARS-CoV-2, like other viruses such as 
avian influenza and SARS-CoV, can infiltrate the mammalian brain-
stem via trans-synaptic transfer which can lead to dysfunction of 
the cardiorespiratory centres of brainstem.2 It has therefore been 
suggested that CNS infiltration of SARS-CoV-2 may explain the de-
terioration of some patient's respiratory effort and their subsequent 
need for ventilation. Hence, close and serial neurological observa-
tions as an adjunct to routine serial observations may prove to be 
an early warning marker of impending deterioration. This of course 
needs further study.
2.4 | Implications on clinical practice
Whilst respiratory symptoms of SARS-CoV-2 are well recognized 
and subsequently protocols are in place to screen for and manage 
these, scope remains for this to be broadened to cover neurological 
symptoms of the disease.
As referenced to previously, the first paper to describe neurolog-
ical involvement in SARS-CoV-2 patients concluded that symptoms 
were much more common in patients with “severe” forms of the 
disease, defined by respiratory symptoms.7 They also reported that 
typical symptoms, such as cough and lethargy, are less pronounced 
in severely unwell patients.7
The implications this has on current clinical practice are therefore 
twofold. Firstly, that all patients, but especially those with “severe” 
SARS-CoV-2, must be monitored for the progression of neurologi-
cal symptoms, as this may indicate a worsening of their condition. 
This should also include coagulation parameters, as suggested by 
Connor's et al due to the predisposition of thrombosis the virus con-
veys. Secondly, that patients presenting with new-onset focal neu-
rology, with or without the presence of coryzal symptoms, should be 
reviewed and treated with suspicion of SARS-CoV-2 infection. This 
will allow the early detection of the disease and therefore preven-
tion of deterioration or transmission.
To fully understanding the impact of SARS-CoV-2 on the ner-
vous system, it is essential that documentation of all neurological 
symptoms is collected for patients infected with the disease, so that 
further analysis can be performed into neurological manifestations. 
An aspect of SARS-CoV-2, not yet fully understood, is the long-term 
sequelae the virus may have on different systems of the body47-50. 
Again, detailed documentation and long-term follow-up of recov-
ered SARS-CoV-2 patients will allow conclusions to be drawn on this 
area.
2.5 | Future research
More data are required to establish the prevalence and, importantly, 
the implications of neurological manifestations in SARS-CoV-2 pa-
tients, both short- and long-term, including mortality rates. As more 
case reports become available, we hope a stronger correlation can 
be established between the two. Diligent documentation of all neu-
rological symptoms is recommended to help achieve this. The mech-
anism underlying the neuroinvolvement of SARS-CoV-2 is also yet 
to be fully understood and remains an area of interest. Identifying 
modes of transmission is essential in possibly reducing spread and 
establishing novel therapeutics, to target the virus.
3  | CONCLUSION
The underlying pathophysiology of neurological manifestations in 
SARS-CoV-2 remains to be fully determined. Increasing numbers of 
papers are reporting neurological involvement in patients, but more 
data are required to adequately correlate the two and the impact 
this has clinically. We recommend close monitoring for neurological 
symptoms and coagulopathy, and to have a low threshold for pa-
tients presenting with new-onset focal neurology, as possible carri-
ers of the disease.
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